Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel Sells 58,283 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 58,283 shares of Alphatec stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This trade represents a 10.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Sponsel also recently made the following trade(s):

• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Trading Up 2.2 %

NASDAQ:ATEC traded up $0.24 on Tuesday, reaching $11.12. The company’s stock had a trading volume of 2,321,717 shares, compared to its average volume of 2,052,927. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The business’s 50-day moving average price is $9.49 and its two-hundred day moving average price is $8.00. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34. The firm has a market cap of $1.58 billion, a PE ratio of -8.69 and a beta of 1.41.

Institutional Investors Weigh In On Alphatec

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATEC. XTX Topco Ltd bought a new stake in Alphatec in the third quarter valued at approximately $69,000. Net Worth Advisory Group acquired a new stake in shares of Alphatec during the 3rd quarter valued at $76,000. Van ECK Associates Corp increased its stake in shares of Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after buying an additional 6,998 shares during the period. Tempus Wealth Planning LLC acquired a new position in shares of Alphatec during the third quarter worth $107,000. Finally, Atria Investments Inc raised its position in shares of Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after acquiring an additional 1,460 shares during the last quarter. 66.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday. Needham & Company LLC boosted their price objective on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Barclays increased their price target on Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Tuesday, November 19th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus target price of $17.44.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.